Vaxcyte Stock Price To Sales

PCVX Stock

USD 112.94 0.62 0.55%

Vaxcyte fundamentals help investors to digest information that contributes to Vaxcyte's financial success or failures. It also enables traders to predict the movement of Vaxcyte Stock. The fundamental analysis module provides a way to measure Vaxcyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vaxcyte stock.

Last Reported

Projected for Next Year

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Vaxcyte Company Price To Sales Analysis

Vaxcyte's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Vaxcyte Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Vaxcyte is extremely important. It helps to project a fair market value of Vaxcyte Stock properly, considering its historical fundamentals such as Price To Sales. Since Vaxcyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vaxcyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vaxcyte's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Long Term Debt	Long Term Debt Total	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Debt	Net Receivables	Deferred Long Term Liab
Total Assets		0.99	0.99	-0.99	0.54	-0.73	-0.73	0.88	0.52	1.0	0.96	0.87	0.82	-0.76	1.0	0.88	0.99	0.82	0.93	0.84
Total Stockholder Equity	0.99		1.0	-0.98	0.54	-0.69	-0.69	0.89	0.42	0.99	0.97	0.88	0.8	-0.78	1.0	0.89	0.99	0.83	0.92	0.85
Net Tangible Assets	0.99	1.0		-0.97	0.57	-0.74	-0.74	0.91	0.44	1.0	0.98	0.89	0.76	-0.82	1.0	0.91	1.0	0.86	0.89	0.86
Retained Earnings	-0.99	-0.98	-0.97		-0.51	0.75	0.75	-0.88	-0.57	-0.97	-0.96	-0.9	-0.86	0.68	-0.98	-0.88	-0.96	-0.82	-0.96	-0.87
Accounts Payable	0.54	0.54	0.57	-0.51		-0.7	-0.7	0.74	0.3	0.57	0.66	0.36	0.36	-0.61	0.56	0.69	0.55	0.76	0.39	0.36
Long Term Debt	-0.73	-0.69	-0.74	0.75	-0.7		1.0	-0.86	-0.63	-0.75	-0.83	-0.74	-0.47	0.65	-0.74	-0.82	-0.73	-0.84	-0.62	-0.73
Long Term Debt Total	-0.73	-0.69	-0.74	0.75	-0.7	1.0		-0.86	-0.63	-0.75	-0.83	-0.74	-0.47	0.65	-0.74	-0.82	-0.73	-0.84	-0.62	-0.73
Capital Surpluse	0.88	0.89	0.91	-0.88	0.74	-0.86	-0.86		0.4	0.89	0.97	0.89	0.61	-0.74	0.9	0.95	0.88	0.97	0.79	0.86
Total Liab	0.52	0.42	0.44	-0.57	0.3	-0.63	-0.63	0.4		0.5	0.46	0.41	0.58	-0.26	0.47	0.45	0.46	0.39	0.53	0.42
Total Current Assets	1.0	0.99	1.0	-0.97	0.57	-0.75	-0.75	0.89	0.5		0.97	0.87	0.77	-0.82	1.0	0.9	1.0	0.84	0.9	0.84
Common Stock	0.96	0.97	0.98	-0.96	0.66	-0.83	-0.83	0.97	0.46	0.97		0.91	0.72	-0.78	0.98	0.95	0.96	0.93	0.88	0.89
Property Plant Equipment	0.87	0.88	0.89	-0.9	0.36	-0.74	-0.74	0.89	0.41	0.87	0.91		0.66	-0.61	0.89	0.87	0.86	0.84	0.86	0.98
Current Deferred Revenue	0.82	0.8	0.76	-0.86	0.36	-0.47	-0.47	0.61	0.58	0.77	0.72	0.66		-0.35	0.79	0.67	0.75	0.59	0.91	0.65
Net Debt	-0.76	-0.78	-0.82	0.68	-0.61	0.65	0.65	-0.74	-0.26	-0.82	-0.78	-0.61	-0.35		-0.79	-0.8	-0.85	-0.76	-0.48	-0.64
Net Invested Capital	1.0	1.0	1.0	-0.98	0.56	-0.74	-0.74	0.9	0.47	1.0	0.98	0.89	0.79	-0.79		0.9	0.99	0.85	0.92	0.86
Capital Stock	0.88	0.89	0.91	-0.88	0.69	-0.82	-0.82	0.95	0.45	0.9	0.95	0.87	0.67	-0.8	0.9		0.9	0.99	0.75	0.91
Net Working Capital	0.99	0.99	1.0	-0.96	0.55	-0.73	-0.73	0.88	0.46	1.0	0.96	0.86	0.75	-0.85	0.99	0.9		0.84	0.87	0.84
Short Term Debt	0.82	0.83	0.86	-0.82	0.76	-0.84	-0.84	0.97	0.39	0.84	0.93	0.84	0.59	-0.76	0.85	0.99	0.84		0.7	0.87
Net Receivables	0.93	0.92	0.89	-0.96	0.39	-0.62	-0.62	0.79	0.53	0.9	0.88	0.86	0.91	-0.48	0.92	0.75	0.87	0.7		0.79
Deferred Long Term Liab	0.84	0.85	0.86	-0.87	0.36	-0.73	-0.73	0.86	0.42	0.84	0.89	0.98	0.65	-0.64	0.86	0.91	0.84	0.87	0.79

Click cells to compare fundamentals

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict Vaxcyte

Price To Sales Ratio Over Time

Based on the latest financial disclosure, Vaxcyte has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.

Vaxcyte Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaxcyte's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaxcyte could also be used in its relative valuation, which is a method of valuing Vaxcyte by comparing valuation metrics of similar companies.

Vaxcyte is currently under evaluation in price to sales category among its peers.

Vaxcyte ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vaxcyte's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vaxcyte's managers, analysts, and investors.

Environmental

Governance

Social

Vaxcyte Fundamentals

	Return On Equity	-0.29
	Return On Asset	-0.2
	Current Valuation	12.55 B
	Shares Outstanding	123.78 M
	Shares Owned By Institutions	100.00 %
	Number Of Shares Shorted	9.34 M
	Price To Book	7.04 X
	Gross Profit	(23 M)
	EBITDA	(464.88 M)
	Net Income	(402.27 M)
	Cash And Equivalents	354.5 M
	Cash Per Share	5.98 X
	Total Debt	29.22 M
	Debt To Equity	0.06 %
	Current Ratio	11.94 X
	Book Value Per Share	17.96 X
	Cash Flow From Operations	(296.79 M)
	Short Ratio	12.28 X
	Earnings Per Share	(4.69) X
	Price To Earnings To Growth	(11.32) X
	Target Price	149.29
	Number Of Employees	254
	Beta	0.99
	Market Capitalization	13.98 B
	Total Asset	1.41 B
	Retained Earnings	(924.39 M)
	Working Capital	950.62 M
	Net Asset	1.41 B

About Vaxcyte Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vaxcyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxcyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxcyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
V	Visa Class A
MSFT	Microsoft

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC